Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 90-99

  Oksjoki, Riina ^a   Laine, Petri ^a,b   Helske, Satu ^a   Vehmaan Kreula, Pirjo ^a   Mäyränpää, Mikko I ^a   Gasque, Philippe ^c   Kovanen, Petri T ^a   Pentikäinen, Markku O ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anaphylatoxins; Atherosclerosis; Complement; Coronary vessels

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MAST CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

ADULT; ATHEROSCLEROSIS; COMPLEMENT SYSTEM PROTEINS; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT;

EID: 34248169999     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.12.016     Document Type: Article

References (35)

1. Buja L.M., and Willerson J.T. Role of inflammation in coronary plaque disruption. Circulation 89 (1994) 503-505
2. Kaartinen M., Penttilä A., and Kovanen P.T. Mast cells accompany microvessels in human coronary atheromas: implications for intimal neovascularization and hemorrhage. Atherosclerosis 123 (1996) 123-131
3. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
4. Vogt W. Anaphylatoxins: possible roles in disease. Complement 3 (1986) 177-188
5. Gasque P., Singhrao S.K., Neal J.W., et al. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150 (1997) 31-41
6. Torzewski M., Torzewski J., Bowyer D.E., et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17 (1997) 2448-2452
7. Laine P., Pentikäinen M.O., Wurzner R., et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 90 (2002) 404-408
8. Yasuda M., Takeuchi K., Hiruma M., et al. The complement system in ischemic heart disease. Circulation 81 (1990) 156-163
9. Kostner K.M., Fahti R.B., Case C., et al. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 365 (2005) 129-134
10. Hoffmeister H.M., Ehlers R., Buttcher E., et al. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol 89 (2002) 909-912
11. Speidl W.S., Exner M., Amighi J., et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 26 (2005) 2294-2299
12. Granger C.B., Mahaffey K.W., Weaver W.D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1190
13. Harvima I.T., Naukkarinen A., Harvima R.J., et al. Immunoperoxidase and enzyme-histochemical demonstration of human skin tryptase in cutaneous mast cells in normal and mastocytoma skin. Arch Dermatol Res 280 (1988) 363-370
14. Saren P., Welgus H.G., and Kovanen P.T. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 157 (1996) 4159-4165
15. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
16. Gasque P., Singhrao S.K., Neal J.W., et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 160 (1998) 3543-3554
17. Crass T., Raffetseder U., Martin U., et al. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 26 (1996) 1944-1950
18. Werfel T., Kirchhoff K., Wittmann M., et al. Activated human T lymphocytes express a functional C3a receptor. J Immunol 165 (2000) 6599-6605
19. Stemme S., Holm J., and Hansson G.K. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 12 (1992) 206-211
20. Patella V., de C.G., Ciccarelli A., et al. Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol 106 (1995) 386-393
21. Zwirner J., Gotze O., Sieber A., et al. The human mast cell line HMC-1 binds and responds to C3a but not C3a(desArg). Scand J Immunol 47 (1998) 19-24
22. Wuepper K.D., Bokisch V.A., Muller-Eberhard H.J., et al. Cutaneous responses to human C 3 anaphylatoxin in man. Clin Exp Immunol 11 (1972) 13-20
23. Ikeda K., Nagasawa K., Horiuchi T., et al. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77 (1997) 394-398
24. Kastl S.P., Speidl W.S., Kaun C., et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost 4 (2006) 1790-1797
25. Godau J., Heller T., Hawlisch H., et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol 173 (2004) 3437-3445
26. Baumann U., Chouchakova N., Gewecke B., et al. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol 167 (2001) 1022-1027
27. Shushakova N., Skokowa J., Schulman J., et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 110 (2002) 1823-1830
28. Ylä-Herttuala S., Palinski W., Butler S.W., et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14 (1994) 32-40
29. Balzo del U.H., Levi R., and Polley M.J. Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci USA 82 (1985) 886-890
30. Balzo del U., Sakuma I., and Levi R. Cardiac dysfunction caused by recombinant human C5A anaphylatoxin: mediation by histamine, adenosine and cyclooxygenase arachidonate metabolites. J Pharmacol Exp Ther 253 (1990) 171-179
31. Lazar H.L., Bokesch P.M., van L.F., et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110 (2004) II274-II279
32. Verrier E.D., Shernan S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291 (2004) 2319-2327
33. Zwaan de C., Kleine A.H., Diris J.H., et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23 (2002) 1670-1677
34. Mahaffey K.W., Granger C.B., Nicolau J.C., et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108 (2003) 1176-1183
35. Theroux P., Armstrong P.W., Mahaffey K.W., et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 26 (2005) 1964-1970